--- title: "Azitra (AZTR) news: reverse split and going concern" url: "https://aibio.space/companies/azitra/" publisher: "aibio.space (Biotech Investor Relations News)" summary: "AZTR reverse split and going concern news: Azitra to carry out 1-for-10 reverse stock split on October 26. Azitra Inc (AMEX: AZTR), United States." --- AZTR Azitra Inc AMEX · United States # Azitra (AZTR) news AZTR reverse split and going concern news Company Updates · 2026-10-29 ## [Azitra expands ATR-04 trial to rash from KRAS and MEK inhibitors](https://aibio.space/news/azitra-expands-atr-04-trial-rash-kras-mek-inhibitors/) Protocol amendments add patients with rash from KRAS and MEK inhibitors, including people with neurofibromatosis type 1, and shorten some washout periods. ## Latest Azitra news 1. 2026-10-22 Listings [Azitra to carry out 1-for-10 reverse stock split on October 26](https://aibio.space/news/azitra-carry-out-1-10-reverse-stock-split-october-26/) Every 10 shares of common stock will combine into one share on NYSE American, with the stock trading on a split-adjusted basis from market open on October 26, 2026. 2. 2026-10-01 Company Updates [Azitra advances ATR-04 trial to Cohort 2 after safety review](https://aibio.space/news/azitra-advances-atr-04-trial-cohort-2-after-safety-review/) The safety review committee recommended moving to Cohort 2 after reviewing safety data from Cohort 1. About 24 patients are expected to enroll in the second cohort. 3. 2026-08-21 Listings [Azitra regains NYSE American continued listing compliance](https://aibio.space/news/azitra-regains-nyse-american-continued-listing-compliance/) NYSE Regulation's August 19, 2026 letter says the company resolved deficiencies under two continued listing standards. A new lapse within 12 months could bring faster action. 4. 2026-07-15 Company Updates [Azitra reports ex vivo skin data for its filaggrin cosmetic ingredient](https://aibio.space/news/azitra-reports-ex-vivo-skin-data-filaggrin-cosmetic-ingredient/) Two ex vivo human skin studies of ATR-COSF showed deeper protein penetration and higher skin elasticity, according to a July 15, 2026 release. A human study is planned next. 5. 2026-06-17 Company Updates [Azitra pauses its Netherton trial and moves capital to cosmetics and proteins](https://aibio.space/news/azitra-pauses-netherton-trial-moves-capital-cosmetics-proteins/) In a letter to shareholders issued June 17, 2026, CEO Francisco Salva said the company will redirect funds from ATR-12 enrollment to a filaggrin cosmetic ingredient and recombinant protein work. 6. 2025-12-17 Listings [NYSE American accepts Azitra's stockholders' equity compliance plan, sets April 1, 2027 deadline](https://aibio.space/news/nyse-american-accepts-azitras-stockholders-equity-compliance-plan-sets/) NYSE American accepted Azitra's plan to restore its $4.0 million minimum stockholders' equity and set April 1, 2027 as the deadline. The stock stays listed while the plan runs, but the company's 2024 annual report carried a going-concern warning. 7. 2025-10-03 Listings [Azitra gets NYSE American notice over minimum stockholders' equity requirement](https://aibio.space/news/azitra-gets-nyse-american-notice-minimum-stockholders-equity/) NYSE American told Azitra on October 1, 2025 that its stockholders' equity of $2.2 million is below the $4.0 million required. The company has until October 31, 2025 to submit a plan, with compliance due by April 1, 2027. Its 2024 annual report carried a going-concern warning. 8. 2025-10-03 Listings [Azitra gets NYSE American notice over $4 million stockholders' equity standard](https://aibio.space/news/azitra-gets-nyse-american-notice-4-million-stockholders-equity/) NYSE American says Azitra is below its $4 million stockholders' equity standard, and the company has until October 31, 2025 to file a plan to restore compliance. ## Azitra at a glance - **Ticker**: AZTR - **Listing**: AMEX - **Country**: United States - **Cash, Jun 30, 2026**: $6.7 million ### Related companies - [RegeneRx Biopharmaceuticals](https://aibio.space/companies/regenerx-biopharmaceuticals/) OTC: RGRX - [Incyte](https://aibio.space/companies/incyte/) NASDAQ: INCY - [Tevogen](https://aibio.space/companies/tevogen/) NASDAQ: TVGN - [Phathom Pharmaceuticals](https://aibio.space/companies/phathom-pharmaceuticals/) NASDAQ: PHAT - [Ultragenyx Pharmaceutical](https://aibio.space/companies/ultragenyx-pharmaceutical/) NASDAQ: RARE - [Biohaven](https://aibio.space/companies/biohaven/) NYSE: BHVN - [ProtoKinetix](https://aibio.space/companies/protokinetix/) OTC: PKTX - [Pyxis Oncology](https://aibio.space/companies/pyxis-oncology/) NASDAQ: PYXS ### Also on AMEX - [Serina Therapeutics](https://aibio.space/companies/serina-therapeutics/) SER - [Protalix BioTherapeutics, Inc. (DE)](https://aibio.space/companies/protalix-biotherapeutics-de/) PLX - [Theriva Biologics](https://aibio.space/companies/theriva-biologics/) TOVX - [MAIA Biotechnology](https://aibio.space/companies/maia-biotechnology/) MAIA - [Armata Pharmaceuticals](https://aibio.space/companies/armata-pharmaceuticals/) ARMP - [Lineage Cell Therapeutics](https://aibio.space/companies/lineage-cell-therapeutics/) LCTX ## What Azitra does Azitra, Inc. is an early-stage clinical biopharmaceutical company developing innovative therapies for precision dermatology using engineered proteins and topical live biotherapeutic products. Its platform includes a microbial library of approximately 1,500 unique bacterial strains that can be screened for therapeutic characteristics, augmented by artificial intelligence and machine learning that analyzes and predicts drug-like molecules. The initial focus is genetically engineered strains of Staphylococcus epidermidis. Its lead program, ATR-12, targets Netherton syndrome, a chronic and sometimes fatal skin disease. ATR-04 targets the papulopustular rash experienced by cancer patients undergoing epidermal growth factor receptor inhibitor therapy, and received Fast Track designation from the FDA. ATR-01 targets ichthyosis vulgaris, where the company completed lead optimization studies in 2025 and continues IND-enabling studies in 2026. Azitra has partnerships with Carnegie Mellon University, which uses artificial intelligence to mine the library for drug-like peptides and proteins, and with Fred Hutchinson Cancer Center, from which it holds an exclusive worldwide license to the SyMPL technologies. The company says it has not commenced commercial operations. | Product or program | What it is | Stage | |---|---|---| | ATR-12 | Genetically modified S. epidermidis strain for Netherton syndrome | Phase 1b/2a; first patient dosed August 2024 | | ATR-04 | Genetically modified S. epidermidis strain for EGFR inhibitor-associated rash | Phase 1/2; Fast Track designation; first patient dosed in the third quarter of 2025 | | ATR-01 | Engineered strain expressing recombinant human filaggrin for ichthyosis vulgaris | IND-enabling studies in 2026 | Summarised from the company's [10-K filed Feb 27, 2026](https://www.sec.gov/Archives/edgar/data/1701478/000170147826000013/aztr-20251231.htm). ## Azitra annual financials | Line | FY2025 | FY2024 | |---|---|---| | Revenue | [$0](https://www.sec.gov/Archives/edgar/data/1701478/000170147826000013/) | [$7,500](https://www.sec.gov/Archives/edgar/data/1701478/000170147826000013/) | | Research and development | [$4.8 million](https://www.sec.gov/Archives/edgar/data/1701478/000170147826000013/) | [$4.7 million](https://www.sec.gov/Archives/edgar/data/1701478/000170147826000013/) | | Net income (loss) | [-$11.0 million](https://www.sec.gov/Archives/edgar/data/1701478/000170147826000013/) | [-$9.0 million](https://www.sec.gov/Archives/edgar/data/1701478/000170147826000013/) | | Cash from operations | [-$11.2 million](https://www.sec.gov/Archives/edgar/data/1701478/000170147826000013/) | [-$10.2 million](https://www.sec.gov/Archives/edgar/data/1701478/000170147826000013/) | | Cash and equivalents | [$2.1 million](https://www.sec.gov/Archives/edgar/data/1701478/000170147826000037/) | [$4.6 million](https://www.sec.gov/Archives/edgar/data/1701478/000170147826000013/) | Latest balance sheet, Jun 30, 2026 (10-Q): cash and equivalents $6.7 million. Figures as reported to the SEC in XBRL; each one links to its filing. Not adjusted, not investment advice. ## Questions about Azitra Did Azitra do a reverse stock split? Our latest story on this, dated Oct 22, 2026: "Azitra to carry out 1-for-10 reverse stock split on October 26". The story links the filing or release it is based on. [Read the story](https://aibio.space/news/azitra-carry-out-1-10-reverse-stock-split-october-26/). Has Azitra issued a going-concern warning? Our latest story on this, dated Dec 17, 2025: "NYSE American accepts Azitra's stockholders' equity compliance plan, sets April 1, 2027 deadline". The story links the filing or release it is based on. [Read the story](https://aibio.space/news/nyse-american-accepts-azitras-stockholders-equity-compliance-plan-sets/). What is the ticker symbol of Azitra? Azitra Inc trades under the ticker AZTR on AMEX. Where is Azitra listed? Azitra Inc is listed on AMEX. What is the SEC CIK of Azitra? The SEC Central Index Key (CIK) for Azitra Inc is 1701478. Its filings are on SEC EDGAR. How many shares does Azitra have outstanding? 60,603,742 shares as of 2026-08-11, per the cover page of its 10-Q filed 2026-08-12. Which country or territory is Azitra listed under? Our directory records Azitra Inc under United States. What does Azitra do? Our directory classifies Azitra Inc as: Pharmaceuticals: Major. This is a directory classification, not a description of the pipeline. What is the ISIN of Azitra? The ISIN recorded for Azitra Inc is US05479L3024. Does aibio.space cover Azitra? aibio.space lists Azitra Inc among 2,820 public biotech companies and publishes its news here as stories appear. Where is Azitra incorporated? SEC records list its state or country of incorporation as DE. What does Azitra develop? Azitra, Inc. is an early-stage clinical biopharmaceutical company developing innovative therapies for precision dermatology using engineered proteins and topical live biotherapeutic products. Its platform includes a microbial library of approximately 1,500 unique bacterial strains that can be screened for therapeutic characteristics, augmented by artificial intelligence and machine learning that analyzes and predicts drug-like molecules. What is ATR-12 from Azitra? ATR-12: Genetically modified S. epidermidis strain for Netherton syndrome Stage: Phase 1b/2a; first patient dosed August 2024. What is ATR-04 from Azitra? ATR-04: Genetically modified S. epidermidis strain for EGFR inhibitor-associated rash Stage: Phase 1/2; Fast Track designation; first patient dosed in the third quarter of 2025. What was Azitra's revenue last year? $0 for the fiscal year ended Dec 31, 2025, as reported to the SEC. ## Investor discussion: Azitra Members talk about Azitra (AZTR). Reader posts, not aibio.space reporting, and not investment advice. Rules 1. **Securities violations are strictly forbidden.** No market manipulation, no pump-and-dump, no false or misleading statements, and no inside information. 2. **Say whether you hold the stock.** Every post states long, short or no position. 3. **No paid or sponsored posts.** Do not post for anyone who pays or rewards you. 4. **No buy or sell calls and no price targets.** 5. **No accusations of crime or fraud against named people** unless you link a court filing or a regulator's release that makes them. 6. **No personal details and no spam.** No links at all for your first 7 days as a member. Posts that break the rules may be deleted without notice, and the account restricted or closed. See the [terms](https://aibio.space/terms/#discussion) and the [privacy policy](https://aibio.space/privacy/#discussion). ## Capital-markets timeline Financings, listing notices, splits, legal actions and other investor events at Azitra, newest first. Each line links the filing it comes from. 1. 2026-10-22 Listings Reported a reverse stock split. SEC Form 8-K (Items 3.03,5.03,9.01). [Source](https://www.sec.gov/Archives/edgar/data/1701478/000149315226048103/form8-k.htm) 2. 2026-08-21 Listings Reported a notice from its stock exchange about continued listing requirements. SEC Form 8-K (Items 8.01,9.01). [Source](https://www.sec.gov/Archives/edgar/data/1701478/000149315226039565/ex99-1.htm) 3. 2026-06-16 Listings Reported a reverse stock split. SEC Form 8-K (Items 5.03,5.07,9.01). [Source](https://www.sec.gov/Archives/edgar/data/1701478/000149315226028814/form8-k.htm) 4. 2026-05-08 Listings Asked shareholders to approve a reverse stock split. SEC Form DEF 14A. [Source](https://www.sec.gov/Archives/edgar/data/1701478/000149315226021980/formdef14a.htm) 5. 2026-04-27 Listings Asked shareholders to approve a reverse stock split. SEC Form PRE 14A. [Source](https://www.sec.gov/Archives/edgar/data/1701478/000149315226019154/formpre14a.htm) 6. 2026-03-23 Financings Reported a financing. SEC Form 8-K (Items 1.01,3.02,5.03,8.01,9.01). [Source](https://www.sec.gov/Archives/edgar/data/1701478/000149315226012084/ex99-1.htm) 7. 2026-03-13 Listings Reported a notice from its stock exchange about continued listing requirements. SEC Form 8-K (Items 3.01,8.01,9.01). [Source](https://www.sec.gov/Archives/edgar/data/1701478/000149315226010108/ex99-1.htm) 8. 2026-02-06 Listings Reported a notice from its stock exchange about continued listing requirements. SEC Form 8-K (Items 8.01,9.01). [Source](https://www.sec.gov/Archives/edgar/data/1701478/000149315226005564/ex99-1.htm) 9. 2025-12-17 Listings Reported a notice from its stock exchange about continued listing requirements. SEC Form 8-K (Items 3.01,8.01,9.01). [Source](https://www.sec.gov/Archives/edgar/data/1701478/000149315225028148/ex99-1.htm) 10. 2025-10-03 Listings Reported a notice from its stock exchange about continued listing requirements. SEC Form 8-K (Items 3.01,8.01,9.01). [Source](https://www.sec.gov/Archives/edgar/data/1701478/000149315225016887/ex99-1.htm) 11. 2025-08-29 Financings Filed a registration statement for a share offering. SEC Form S-1. [Source](https://www.sec.gov/Archives/edgar/data/1701478/000149315225012495/forms-1.htm) 12. 2025-08-20 Listings Reported a reverse stock split. SEC Form 8-K (Items 3.03,5.03,9.01). [Source](https://www.sec.gov/Archives/edgar/data/1701478/000149315225012191/form8-k.htm) 13. 2025-04-24 Financings Reported an unregistered sale of its securities. SEC Form 8-K (Items 1.01,3.02,8.01,9.01). [Source](https://www.sec.gov/Archives/edgar/data/1701478/000164117225006043/ex99-1.htm) 14. 2025-02-20 Listings Reported a shareholder vote on a reverse stock split or more authorized shares. SEC Form 8-K (Items 5.07). [Source](https://www.sec.gov/Archives/edgar/data/1701478/000149315225007717/form8-k.htm) 15. 2025-01-14 Listings Asked shareholders to approve a reverse stock split. SEC Form DEF 14A. [Source](https://www.sec.gov/Archives/edgar/data/1701478/000149315225002139/formdef14a.htm) 16. 2025-01-03 Listings Asked shareholders to approve a reverse stock split. SEC Form PRE 14A. [Source](https://www.sec.gov/Archives/edgar/data/1701478/000149315225000263/formpre14a.htm) ## Press releases Headlines of Azitra's own announcements, newest first. Each opens the full release on the newswire that carried it. 1. 2026-10-29 PR Newswire [Azitra, Inc. Expands Eligibility for ATR-04 Phase 1/2 Clinical Trial to Include Patients with Rashes due to KRAS and MEK Inhibitors](https://www.prnewswire.com/news-releases/azitra-inc-expands-eligibility-for-atr-04-phase-12-clinical-trial-to-include-patients-with-rashes-due-to-kras-and-mek-inhibitors-302922983.html) 2. 2026-10-26 PR Newswire [Azitra, Inc. Announces Revitalizing Results from Ex Vivo Study of ATR-COSF Demonstrating Ability to Reduce Fine Lines and Improve Elasticity in Human Skin](https://www.prnewswire.com/news-releases/azitra-inc-announces-revitalizing-results-from-ex-vivo-study-of-atr-cosf-demonstrating-ability-to-reduce-fine-lines-and-improve-elasticity-in-human-skin-302918813.html) ## Stock chart Price chart and quote supplied by TradingView, delayed as the exchange requires. It loads only if you choose to show it. Information only, not investment advice. [Open AMEX:AZTR on TradingView](https://www.tradingview.com/symbols/AMEX-AZTR/). ## SEC filings and registration - **SEC name**: Azitra, Inc. - **CIK**: 1701478 - **Industry (SIC)**: Pharmaceutical Preparations (2834) - **US tickers**: AZTR (NYSE) - **State or country of incorporation**: DE - **Fiscal year ends**: December 31 - **Filer category**:
Emerging growth company - **Business address**: 21 BUSINESS PARK DRIVE, SUITE 6, BRANFORD, CT, 06405 - **Phone**: (203) 489-0183 - **Shares outstanding**: 60,603,742 as of 2026-08-11 (10-Q filed 2026-08-12) - **Former names**: Azitra Inc ### Recent filings (8-K and 6-K are the company's own announcements) - [8-K](https://www.sec.gov/Archives/edgar/data/1701478/000149315226048103/form8-k.htm) filed 2026-10-22 - [8-K](https://www.sec.gov/Archives/edgar/data/1701478/000149315226045260/form8-k.htm) filed 2026-10-01 - [8-K](https://www.sec.gov/Archives/edgar/data/1701478/000149315226044605/form8-k.htm) filed 2026-09-28 - [424B5](https://www.sec.gov/Archives/edgar/data/1701478/000149315226044593/form424b5.htm) filed 2026-09-28 - [8-K](https://www.sec.gov/Archives/edgar/data/1701478/000149315226041706/form8-k.htm) filed 2026-09-08 - [8-K](https://www.sec.gov/Archives/edgar/data/1701478/000149315226039565/form8-k.htm) filed 2026-08-21 - [8-K](https://www.sec.gov/Archives/edgar/data/1701478/000170147826000039/aztr-20260812.htm) filed 2026-08-12 - [10-Q](https://www.sec.gov/Archives/edgar/data/1701478/000170147826000037/aztr-20260630.htm) filed 2026-08-12 Source: [SEC EDGAR](https://www.sec.gov/cgi-bin/browse-edgar?action=getcompany&CIK=0001701478), retrieved October 23, 2026. Shares outstanding is the cover-page figure from the latest periodic report. The SEC does not publish share prices. ## Listing details Azitra Inc is a public biotech or pharmaceutical company listed on AMEX under the ticker AZTR, recorded under United States. The directory classifies it as Pharmaceuticals: Major. aibio.space tracks 2,820 public biotech companies worldwide and publishes investor news on them. - **Company**: Azitra Inc - **Ticker**: AZTR - **Listing**: AMEX - **Country or territory**: United States - **Business scope**: Pharmaceuticals: Major - **ISIN**: US05479L3024 - **Last quote in directory**: 2026-10-13 - **Directory source**: [Listing page](https://www.tradingview.com/symbols/AMEX-AZTR/) Listing facts come from our company directory, researched on October 22, 2026. A listing record does not certify that a security currently trades. [Tell us about a change](https://aibio.space/reputation/#update). Work at this company? [Claim this page](https://aibio.space/claim/). Published and maintained by aibio.space. Not investment advice. [How we work](https://aibio.space/disclosures/). Who manages this page **This page is managed by aibio.space.** The company does not run, edit or pay for this page. News, desk views and Investor Ranks are written and managed independently by aibio.space under our editorial and analytical judgment. Opinion only, not investment advice. [How we work](https://aibio.space/disclosures/#paid) · [Terms](https://aibio.space/terms/#news) · [Request a correction](https://aibio.space/reputation/#update) --- Source page: https://aibio.space/companies/azitra/. Facts in aibio.space stories are checked against company filings and releases; opinion is labelled. Cite as: aibio.space, "Azitra (AZTR) news: reverse split and going concern", 2026-10-31, https://aibio.space/companies/azitra/